APO RESEARCH · REPORT
Biosimilar Insulin
Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product's patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.
Product & engineering
Understand the product.
Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product's patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.
Selected research
Industry Research
Biosimilar Insulin Industry Research Report 2026
Market perspective
Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product's patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.
Global Biosimilar Insulin key players include Biocon, Gan&Lee, Wockhardt, Eli Lilly, Sanofi etc. Global top three players hold a share over 70%. India is the largest market, with a share about 30%, followed by Southeast Asia and China, both have a share about 40 percent
Report Scope
Read the full market overview
This report quantifies the global Biosimilar Insulin market in terms of revenue (US$ million) and, where applicable, sales volume (K Unit), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Unit) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Biosimilar Insulin Market by Company
Eli Lilly
Sanofi
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt
Biosimilar Insulin Segment by Type
Biosimilar Insulin Glargine
Biosimilar Insulin Lispro
Other
Biosimilar Insulin Segment by Distribution Channel
Hospital
Retail Pharmacy
Others
Biosimilar Insulin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Insulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilar Insulin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Insulin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Biosimilar Insulin manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Biosimilar Insulin by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Biosimilar Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by distribution channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Biosimilar Insulin Glargine
- Biosimilar Insulin Lispro
- Other
Applications
- Hospital
- Retail Pharmacy
- Others
Companies covered
- Eli Lilly
- Sanofi
- Gan&Lee
- Tonghua Dongbao
- United Laboratory
- Geropharm
- Biocon
- Wockhardt
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Biosimilar Insulin Market Size (2021-2032)
- 2.2.2 Global Biosimilar Insulin Sales (2021-2032)
- 2.2.3 Global Biosimilar Insulin Market Average Price (2021-2032)
- 2.3 Biosimilar Insulin by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Biosimilar Insulin Glargine
- 2.3.3 Biosimilar Insulin Lispro
- 2.3.4 Other
- 2.4 Biosimilar Insulin by Distribution Channel
- 2.4.1 Market Value Comparison by Distribution Channel (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Retail Pharmacy
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Biosimilar Insulin Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Biosimilar Insulin Sales (K Unit) of Manufacturers (2021-2026)
- 3.3 Global Biosimilar Insulin Revenue of Manufacturers (2021-2026)
- 3.4 Global Biosimilar Insulin Average Price by Manufacturers (2021-2026)
- 3.5 Global Biosimilar Insulin Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Biosimilar Insulin, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Biosimilar Insulin, Product Type & Application
- 3.8 Global Manufacturers of Biosimilar Insulin, Established Date
- 3.9 Global Biosimilar Insulin Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Eli Lilly
- 4.1.1 Eli Lilly Company Information
- 4.1.2 Eli Lilly Business Overview
- 4.1.3 Eli Lilly Biosimilar Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Eli Lilly Biosimilar Insulin Product Portfolio
- 4.1.5 Eli Lilly Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Biosimilar Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi Biosimilar Insulin Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Gan&Lee
- 4.3.1 Gan&Lee Company Information
- 4.3.2 Gan&Lee Business Overview
- 4.3.3 Gan&Lee Biosimilar Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Gan&Lee Biosimilar Insulin Product Portfolio
- 4.3.5 Gan&Lee Recent Developments
- 4.4 Tonghua Dongbao
- 4.4.1 Tonghua Dongbao Company Information
- 4.4.2 Tonghua Dongbao Business Overview
- 4.4.3 Tonghua Dongbao Biosimilar Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Tonghua Dongbao Biosimilar Insulin Product Portfolio
- 4.4.5 Tonghua Dongbao Recent Developments
- 4.5 United Laboratory
- 4.5.1 United Laboratory Company Information
- 4.5.2 United Laboratory Business Overview
- 4.5.3 United Laboratory Biosimilar Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 United Laboratory Biosimilar Insulin Product Portfolio
- 4.5.5 United Laboratory Recent Developments
- 4.6 Geropharm
- 4.6.1 Geropharm Company Information
- 4.6.2 Geropharm Business Overview
- 4.6.3 Geropharm Biosimilar Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Geropharm Biosimilar Insulin Product Portfolio
- 4.6.5 Geropharm Recent Developments
- 4.7 Biocon
- 4.7.1 Biocon Company Information
- 4.7.2 Biocon Business Overview
- 4.7.3 Biocon Biosimilar Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Biocon Biosimilar Insulin Product Portfolio
- 4.7.5 Biocon Recent Developments
- 4.8 Wockhardt
- 4.8.1 Wockhardt Company Information
- 4.8.2 Wockhardt Business Overview
- 4.8.3 Wockhardt Biosimilar Insulin Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Wockhardt Biosimilar Insulin Product Portfolio
- 4.8.5 Wockhardt Recent Developments
5 Global Biosimilar Insulin Market Scenario by Region
- 5.1 Global Biosimilar Insulin Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Biosimilar Insulin Sales by Region: 2021-2032
- 5.2.1 Global Biosimilar Insulin Sales by Region: 2021-2026
- 5.2.2 Global Biosimilar Insulin Sales by Region: 2027-2032
- 5.3 Global Biosimilar Insulin Revenue by Region: 2021-2032
- 5.3.1 Global Biosimilar Insulin Revenue by Region: 2021-2026
- 5.3.2 Global Biosimilar Insulin Revenue by Region: 2027-2032
- 5.4 North America Biosimilar Insulin Market Facts & Figures by Country
- 5.4.1 North America Biosimilar Insulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Biosimilar Insulin Sales by Country (2021-2032)
- 5.4.3 North America Biosimilar Insulin Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Biosimilar Insulin Market Facts & Figures by Country
- 5.5.1 Europe Biosimilar Insulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Biosimilar Insulin Sales by Country (2021-2032)
- 5.5.3 Europe Biosimilar Insulin Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Biosimilar Insulin Market Facts & Figures by Country
- 5.6.1 Asia Pacific Biosimilar Insulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Biosimilar Insulin Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Biosimilar Insulin Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Biosimilar Insulin Market Facts & Figures by Country
- 5.7.1 South America Biosimilar Insulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Biosimilar Insulin Sales by Country (2021-2032)
- 5.7.3 South America Biosimilar Insulin Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Biosimilar Insulin Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Biosimilar Insulin Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Biosimilar Insulin Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Biosimilar Insulin Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Biosimilar Insulin Sales by Type (2021-2032)
- 6.1.1 Global Biosimilar Insulin Sales by Type (2021-2032) & (K Unit)
- 6.1.2 Global Biosimilar Insulin Sales Market Share by Type (2021-2032)
- 6.2 Global Biosimilar Insulin Revenue by Type (2021-2032)
- 6.2.1 Global Biosimilar Insulin Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Biosimilar Insulin Revenue Market Share by Type (2021-2032)
- 6.3 Global Biosimilar Insulin Price by Type (2021-2032)
7 Segment by Distribution Channel
- 7.1 Global Biosimilar Insulin Sales by Distribution Channel (2021-2032)
- 7.1.1 Global Biosimilar Insulin Sales by Distribution Channel (2021-2032) & (K Unit)
- 7.1.2 Global Biosimilar Insulin Sales Market Share by Distribution Channel (2021-2032)
- 7.2 Global Biosimilar Insulin Revenue by Distribution Channel (2021-2032)
- 7.2.1 Global Biosimilar Insulin Sales by Distribution Channel (2021-2032) & (US$ Million)
- 7.2.2 Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2021-2032)
- 7.3 Global Biosimilar Insulin Price by Distribution Channel (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Biosimilar Insulin Value Chain Analysis
- 8.1.1 Biosimilar Insulin Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Biosimilar Insulin Production Mode & Process
- 8.2 Biosimilar Insulin Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Biosimilar Insulin Distributors
- 8.2.3 Biosimilar Insulin Customers
9 Global Biosimilar Insulin Analyzing Market Dynamics
- 9.1 Biosimilar Insulin Industry Trends
- 9.2 Biosimilar Insulin Industry Drivers
- 9.3 Biosimilar Insulin Industry Opportunities and Challenges
- 9.4 Biosimilar Insulin Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst